Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pharmather Hldgs Ltd (PHRM.CN)

Pharmather Hldgs Ltd (PHRM.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 19,032
  • Shares Outstanding, K 88,519
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,416 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 2.89
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.73

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1850 +18.92%
on 10/23/24
0.3150 -30.16%
on 10/21/24
-0.0700 (-24.14%)
since 10/18/24
3-Month
0.1800 +22.22%
on 08/30/24
0.3300 -33.33%
on 09/30/24
-0.0100 (-4.35%)
since 08/16/24
52-Week
0.1200 +83.33%
on 11/20/23
0.4300 -48.84%
on 03/19/24
+0.1050 (+91.30%)
since 11/17/23

Most Recent Stories

More News
PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application

PHRM.CN : 0.2200 (+2.33%)
PHRRF : 0.1600 (+5.54%)
PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application

PHRM.CN : 0.2200 (+2.33%)
PHRRF : 0.1600 (+5.54%)
PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases

Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development...

PHRRF : 0.1600 (+5.54%)
LMLLF : 0.0142 (+12.70%)
PHRM.CN : 0.2200 (+2.33%)
PHRX.CN : 0.0200 (+33.33%)
Stocks in play: PharmaTher Inc

Today submitted its meeting package with the U.S. Food and Drug Administration to discuss advancing ...

PHRM.CN : 0.2200 (+2.33%)
PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders

TORONTO, July 13, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty...

PHRRF : 0.1600 (+5.54%)
PHRM.CN : 0.2200 (+2.33%)
PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

Successfully delivered ketamine and KETABET™ (ketamine and betaine) via microneedle patch, unlocking the potential for desired dosage forms and...

PHRM.CN : 0.2200 (+2.33%)
PHRRF : 0.1600 (+5.54%)
PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO

Wearable ketamine delivery device complements PharmaTher’s ketamine product portfolio, including injectable, intravenous, and microneedle patch PharmaTher...

PHRM.CN : 0.2200 (+2.33%)
PHRRF : 0.1600 (+5.54%)
PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion product,...

PHRM.CN : 0.2200 (+2.33%)
PHRRF : 0.1600 (+5.54%)
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs

PharmaTher to file ANDA and 505(b)(2) regulatory submissions with the FDA for novel uses, delivery forms and formulations of ketamine for mental health,...

PHRRF : 0.1600 (+5.54%)
PHRM.CN : 0.2200 (+2.33%)
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease

100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was well...

PHRM.CN : 0.2200 (+2.33%)
PHRRF : 0.1600 (+5.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

PharmaTher Holdings Ltd is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat mental health, neurological, and pain disorders. Its product pipeline includes Ketamine, KETABET, Microneedle Patch among others.

See More

Key Turning Points

3rd Resistance Point 0.2350
2nd Resistance Point 0.2300
1st Resistance Point 0.2250
Last Price 0.2200
1st Support Level 0.2150
2nd Support Level 0.2100
3rd Support Level 0.2050

See More

52-Week High 0.4300
Fibonacci 61.8% 0.3116
Fibonacci 50% 0.2750
Fibonacci 38.2% 0.2384
Last Price 0.2200
52-Week Low 0.1200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar